12:00 AM
Oct 11, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FMdC: Phase II

Preliminary data from MATX's Phase II study showed that FMdC did not give meaningful clinical activity as a stand-alone therapy....

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >